(VIANEWS) – Noah Holdings Limited (NOAH), Hyatt Hotels Corporation (H), Boston Scientific (BSX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Noah Holdings Limited (NOAH)
33.2% sales growth and 9.42% return on equity
Noah Holdings Limited, together with its subsidiaries, operates as a wealth and asset management service provider with the focus on investment and asset allocation services for high net worth individuals and enterprises in Mainland of China, Hong Kong, and internationally. It operates through three segments: Wealth Management, Asset Management, and Other Businesses. The company offers investment products, including domestic and overseas publicly raised and public securities investment funds, privately-raised investment funds, and private equity products; customized value-added financial services, such as investor education and trust services, as well as insurance brokerage services; and insurance products. It also provides onshore and offshore private equity, real estate, public securities, multi-strategy, and other investment products, as well as lending services. The company was founded in 2005 and is headquartered in Shanghai, the People's Republic of China.
Earnings Per Share
As for profitability, Noah Holdings Limited has a trailing twelve months EPS of $1.9.
PE Ratio
Noah Holdings Limited has a trailing twelve months price to earnings ratio of 6.65. Meaning, the purchaser of the share is investing $6.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.42%.
Sales Growth
Noah Holdings Limited’s sales growth for the next quarter is 33.2%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 25, 2023, the estimated forward annual dividend rate is 0.38 and the estimated forward annual dividend yield is 3.03%.
Moving Average
Noah Holdings Limited’s worth is above its 50-day moving average of $12.31 and way under its 200-day moving average of $14.71.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Noah Holdings Limited’s EBITDA is 0.05.
2. Hyatt Hotels Corporation (H)
11.1% sales growth and 13.87% return on equity
Hyatt Hotels Corporation operates as a hospitality company in the United States and internationally. It operates through Owned and Leased Hotels, Americas Management and Franchising, ASPAC Management and Franchising, EAME/SW Asia Management and Franchising, and Apple Leisure Group segments. The company manages, franchises, licenses, owns, and leases portfolio of properties, consisting of full-service hotels, select service hotels, resorts, and other properties, including timeshare, fractional, residential, vacation, and condominium units. It operates its properties under the Park Hyatt, Miraval, Grand Hyatt, Alila, Andaz, The Unbound Collection by Hyatt, Destination, Hyatt Regency, Hyatt, Thompson Hotels, Hyatt Centric, Joie de Vivre, Caption by Hyatt, Hyatt House, Hyatt Place, Hyatt Ziva, Hyatt Zilara, UrCove, Hyatt Residence Club, Hyatt Residences, Hyatt Resorts, Secrets Resorts & Spas, Dreams Resorts & Spas, Breathless Resorts & Spas, Zoetry Wellness & Spa Resorts, Alua Hotels & Resorts, and Sunscape Resorts & Spas brands. As of September 30, 2022, the company's hotel portfolio consisted of approximately 1,200 hotels in 72 countries across six continents. It primarily serves corporations; national, state, and regional associations; specialty market accounts, including social, government, military, educational, religious, and fraternal organizations; travel agency and luxury organizations; and a group of individual consumers. The company also operates World of Hyatt loyalty program which rewards points that can be redeemed for hotel nights and other rewards. Hyatt Hotels Corporation was founded in 1957 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Hyatt Hotels Corporation has a trailing twelve months EPS of $4.45.
PE Ratio
Hyatt Hotels Corporation has a trailing twelve months price to earnings ratio of 26.54. Meaning, the purchaser of the share is investing $26.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.87%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 83.5% and positive 87.8% for the next.
3. Boston Scientific (BSX)
8% sales growth and 6.68% return on equity
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Per Share
As for profitability, Boston Scientific has a trailing twelve months EPS of $0.82.
PE Ratio
Boston Scientific has a trailing twelve months price to earnings ratio of 67.87. Meaning, the purchaser of the share is investing $67.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.68%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 13.76B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 4.1% and 10.6%, respectively.
Previous days news about Boston Scientific(BSX)
- Boston Scientific (bsx) hits 52-week high: what's aiding it?. According to Zacks on Thursday, 14 December, "Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. ", "Geographic Expansion: Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States, raising investors’ optimism. "
4. Calix (CALX)
7% sales growth and 6.84% return on equity
Calix, Inc., together with its subsidiaries, provides cloud and software platforms, and systems and services in the United States, the Middle East, Canada, Europe, the Caribbean, and internationally. The company's cloud and software platforms, and systems and services enable communication service providers (CSPs) to provide a range of services. It provides Calix Cloud platform, a role-based analytics platform comprising Calix Marketing Cloud, Calix Support Cloud, and Calix Operations Cloud, which are configurable to display role-based insights and enable CSPs to anticipate and target new revenue-generating services and applications through mobile application. The company also offers EXOS, a carrier class smart home and business operating system that supports residential, business, and mobile subscribers; and AXOS, an operating system for access networks that allows a service provider to deliver all services on a single, elastic, converged access network that is always on, simple to operate, and quick to deploy. It offers its products through its direct sales force and resellers. Calix, Inc. was incorporated in 1999 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, Calix has a trailing twelve months EPS of $0.7.
PE Ratio
Calix has a trailing twelve months price to earnings ratio of 56.46. Meaning, the purchaser of the share is investing $56.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.84%.
Volume
Today’s last reported volume for Calix is 433528 which is 40.95% below its average volume of 734185.
Moving Average
Calix’s value is below its 50-day moving average of $39.91 and way under its 200-day moving average of $45.78.
5. Incyte Corporation (INCY)
5.4% sales growth and 9.28% return on equity
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Earnings Per Share
As for profitability, Incyte Corporation has a trailing twelve months EPS of $1.88.
PE Ratio
Incyte Corporation has a trailing twelve months price to earnings ratio of 33.1. Meaning, the purchaser of the share is investing $33.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.
